Andrew Chan

Andrew Chan at MGH has been the leading researcher on aspirin as a cancer prevention agent, particularly for colorectal cancer. His large observational studies and analysis of randomized trial data have contributed to the growing evidence that regular aspirin use reduces colorectal cancer incidence and mortality, with the mechanism likely involving COX-2 inhibition and prostaglandin pathway effects. The USPSTF recommendations on aspirin for CRC prevention involve complex tradeoffs with gastrointestinal and cerebrovascular bleeding risks.